Form 4: Enanta Pharmaceuticals CEO Sells Shares to Cover Tax Obligations
Form 4 Filing
Enanta Pharmaceuticals CEO, Jay R. Luly, sold shares to cover withholding taxes related to a restricted stock unit award.
Summary
- Enanta Pharmaceuticals CEO, Jay R. Luly, sold 5,142 shares of common stock on December 6, 2024.
- The shares were sold to cover withholding taxes due as a result of the settlement of a portion of a restricted stock unit award granted on November 23, 2022.
- The sale was not a discretionary transaction but rather a 'sell to cover' transaction to satisfy tax withholding obligations.
- The shares were sold at a weighted-average price of $8.06, with individual transactions ranging from $7.87 to $8.22.
Sentiment
Score: 5
Explanation: The document describes a routine transaction related to executive compensation and tax obligations. It is neither particularly positive nor negative for the company's outlook.
Risks
- Executive share sales, even for tax purposes, can sometimes be perceived negatively by the market.
Management Comments
- The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the reporting person.
Industry Context
Executive stock sales are a common occurrence, especially when related to vesting of stock awards and tax obligations. This transaction is not unusual for a company of this size and stage.
Comparison to Industry Standards
- Executive stock sales for tax purposes are a standard practice across the pharmaceutical industry.
- Companies like Gilead Sciences and Vertex Pharmaceuticals also see similar transactions from their executives.
- The size of the transaction is relatively small compared to the overall market capitalization of Enanta Pharmaceuticals.
Stakeholder Impact
- The stock sale has a minimal impact on shareholders as it is a small transaction related to tax obligations.
Key Dates
| Date | Description |
|---|---|
| 2022-11-23 | Date of the restricted stock unit award grant. |
| 2024-12-06 | Date of the stock sale by the CEO. |
| 2024-12-10 | Date of the filing of the Form 4. |
Keywords
Enanta Pharmaceuticals, CEO, Jay R. Luly, stock sale, restricted stock unit, tax withholding, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.